H.R. 2286: American Genetic Privacy Act of 2025
The American Genetic Privacy Act of 2025 aims to restrict the sharing of certain genetic information with the People's Republic of China. This legislation outlines the following key components:
Prohibition on Disclosure
- Sales of Information: No individual or organization is allowed to sell or offer to sell genetic information to the People's Republic of China or to any entity that is influenced, controlled, or owned by the People's Republic of China.
- Disclosures by DNA Testing Services: Commercial DNA testing services are prohibited from disclosing genetic information to the People's Republic of China or to any entities influenced, controlled, or owned by it.
Enforcement Mechanism
The Federal Trade Commission (FTC) will be responsible for enforcing these prohibitions. A violation of this law will be treated as a violation of existing regulations under the Federal Trade Commission Act regarding unfair or deceptive practices.
- The FTC will have the same powers and jurisdiction to enforce this section as it does under its existing authority, enabling it to impose penalties for violations.
Definitions
- Commercial DNA Testing Service: A service that provides genealogical or ancestry-related information based on an individual’s DNA.
- Covered Information: This refers to genetic information originally acquired from an individual through the use of a commercial DNA testing service.
- Genetic Information: Information regarding the genetic tests of an individual.
- Genetic Test: Defined as per existing law under the Genetic Information Nondiscrimination Act of 2008.
Relevant Companies
- AMGN (Amgen Inc.): As a biotechnology company involved in genetic research, Amgen may be affected by regulations related to the sharing of genetic information and how they conduct research and collaborations.
- ILMN (Illumina Inc.): As a leader in genetic sequencing technology, the impact on legal and operational frameworks regarding genetic data privacy could significantly affect their business operations and data sharing agreements.
- EXAS (Exact Sciences Corporation): This company focuses on cancer screening and genetic testing and may face implications regarding how it handles genetic data and compliance with new regulations.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
4 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Mar. 24, 2025 | Introduced in House |
| Mar. 24, 2025 | Referred to the House Committee on Energy and Commerce. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
